Companies: 10,795·Total market cap: $144.5T
NovaBridge Biosciences

NovaBridge Biosciences

NBPNASDAQHealthcare● Active
$1.56
$-0.09(-5.17%)
Market Cap$179815043
P/E Ratio
52W High$6.79
52W Low$1.53

NovaBridge Biosciences (NBP) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

nbp · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for NovaBridge Biosciences (NBP) measures how much investors pay for each dollar of the company's trailing earnings. NBP's current PE ratio of N/A is calculated by dividing its stock price of $1.56 by its TTM earnings per share of -$0.40.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-5.02
Based on 1 analyst
EPS (TTM)
-$0.40
TTM · diluted EPS
PEG Ratio
0.25
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NovaBridge Biosciences SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2017 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 44.6x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
NovaBridge Biosciences
NovaBridge BiosciencesYou
NBP
$180MN/A-$0.40
Altimmune, Inc.
Altimmune, Inc.
ALT
$241MN/A-$1.00
Annexon, Inc.
Annexon, Inc.
ANNX
$612MN/A-$1.33
Aura Biosciences, Inc.
Aura Biosciences, Inc.
AURA
$416MN/A-$1.76
DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc.
DMAC
$302MN/A-$0.70
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd.
DRTS
$838MN/A-$0.53
Design Therapeutics, Inc.
Design Therapeutics, Inc.
DSGN
$653MN/A-$1.22

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 9 of 9 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.16
2024-12-31
FY2024
$-2.00
2023-12-31
FY2023
$-17.62
2022-12-31
FY2022
$-30.39
2021-12-31
FY2021
$-30.70
2020-12-31
FY2020
44.59x$6.90
2019-12-31
FY2019
$-24.89
2018-12-31
FY2018
$-6.92
2017-12-31
FY2017
$-5.13

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for NovaBridge Biosciences (NBP) measures how much investors pay for each dollar of the company's trailing earnings. NBP's current PE ratio of N/A is calculated by dividing its stock price of $1.56 by its TTM earnings per share of -$0.40.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.56 ÷ -$0.40 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

NBP pe ratio · 6 questions

NBP's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.56 and TTM EPS of -$0.40. Data sourced from Financial Modeling Prep via NBP's SEC 10-K and 10-Q filings.

NBP PE ratioWhat is NBP PE ratioCurrent PE ratio of NBPNBP PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NovaBridge Biosciences SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09